Management of Helicobacter pylori infection in primary care in Spain;Manejo de la infección por Helicobacter pylori en atención primaria en España

Gastroenterologia y Hepatologia

Volumn 31, Issue 6, 2008, Pages 327-334

  Gené Tous, Emili ^a,b,c,e   Sánchez Delgado, Jordi ^a,b,c   Calvet, Xavier ^a,b,c   Azagra, Rafael ^d  

^a PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d Health Center Badia del Valles ICS GROIMAP USR MN IDIAP Jordi Gol   (Spain)

^e HOSPITAL DE SABADELL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; PROTON PUMP INHIBITOR; STOMACH SECRETION INHIBITOR;

ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DIAGNOSTIC TEST; DRUG INTERMITTENT THERAPY; DUODENUM ULCER; ERADICATION THERAPY; FECES ANALYSIS; GASTROESOPHAGEAL REFLUX; GASTROSCOPY; HEALTH CARE ACCESS; HEALTH CARE PERSONNEL; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PATHOGENESIS; PRIMARY MEDICAL CARE; SEROLOGY; SPAIN; STOMACH ULCER; STRUCTURED QUESTIONNAIRE; TREATMENT DURATION; TREATMENT INDICATION; UREA BREATH TEST;

EID: 48249130061     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1157/13123599     Document Type: Article

References (31)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311-5.
2. Goodwin CS, Armstrong JA, Marshall BJ. Campylobacter pyloridis, gastritis, and peptic ulceration. J Clin Pathol. 1986;39:353-65.
3. Marshall BJ. The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer. JAMA. 1995;274:1064-6.
4. Forbes GM, Glaser ME, Cullen DJ, Warren JR, Christiansen KJ, Marshall BJ, et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet. 1994;343:258-60.
5. Van der Hulst RW, Rauws EA, Koycu B, Keller JJ, Bruno MJ, Tijssen JG, et al. Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study. Gastroenterology. 1997;113:1082-6.
6. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167-80.
7. Mones J, Gisbert JP, Borda F, Domínguez-Muñoz E. Indications, diagnostic tests and Helicobacter pylori eradication therapy. Recommendations by the 2nd Spanish Consensus Conference. Rev Esp Enferm Dig. 2005;97:348-74.
8. Gisbert JP, Calvet X, Gomollon F, Sainz R. Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la Conferencia Española de Consenso. Med Clin (Barc). 2000;114:185-95.
9. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998;93:2330-8.
10. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. JAMA. 1994;272:65-9.
11. Azagra R, Barenys M, Benavent J, Bordas JM, Forne M, Mascort JJ. Guia de pràctica clínica per al diagnòstic i tractament de la dispèpsia i les malalties relacionades amb la infecció per Helicobacter pylori a l'atenció primària. Barcelona: Societat Catalana de Medicina Familiar i Comunitària i Societat Catalana de Digestologia; 2000, 2006.
12. Gisbert JP, Calvet X, Gomollon F, Mones J. Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la II Conferencia Española de Consenso. Med Clin (Barc). 2005;125:301-16.
13. Thamer M, Ray NF, Henderson SC, Rinehart CS, Sherman CR, Ferguson JH. Influence of the NIH Consensus Conference on Helicobacter pylori on physician prescribing among a Medicaid population. Med Care. 1998;36:646-60.
14. Lee JM, Deasy E, O'Morain CA. Helicobacter pylori eradication therapy: a discrepancy between current guidelines and clinical practice. Eur J Gastroenterol Hepatol. 2000;12:433-7.
15. Breuer T, Goodman KJ, Malaty HM, Sudhop T, Graham DY. How do clinicians practicing in the US manage Helicobacter pylori-related gastrointestinal diseases? A comparison of primary care and specialist physicians. Am J Gastroenterol. 1998;93:553-61.
16. Martínez-Sánchez G, Saperas E, Benavent J, Mearin F, Pinol JL, Barenys M, et al. Actitud de los médicos de atención primaria del área metropolitana de Barcelona frente al diagnóstico y tratamiento de la infección por Helicobacter pylori en enfermedades gastroduodenales. Gastroenterol Hepatol. 1998;21:473-8.
17. Gené E, Calvet X, Azagra R, López T, Cubells MJ. Manejo de la dispepsia, la enfermedad ulcerosa y la infección por Helicobacter pylori en atención primaria. Aten Primaria. 2002;29:486-94.
18. Anuario de la Sanidad y del Medicamento en España. El Médico. Profesión y Humanidades. 2005. p. 949.
19. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol. 2005;100:1696-701.
20. Fendrick AM, Hirth RA, Chernew ME. Differences between generalist and specialist physicians regarding Helicobacter pylori and peptic ulcer disease. Am J Gastroenterol. 1996;91:1544-8.
21. Azagra R, Gené E, Bonet JM, Sole F, Calvet X. Beneficios del tratamiento erradicador de la infección por Helicobacter pylori en pacientes ulcerosos en un centro de atención primaria. Aten Primaria. 2000;25:377-82.
22. Breuer T, Sudhop T, Goodman KJ, Graham DY, Malfertheiner P. How do practicing clinicians manage Helicobacter pylori-related gastrointestinal diseases in Germany? A survey of gastroenterologists and family practitioners. Helicobacter. 1998; 3:1-8.
23. Hirth RA, Fendrick AM, Chernew ME. Specialist and generalist physicians' adoption of antibiotic therapy to eradicate Helicobacter pylori infection. Med Care. 1996;34:1199-204.
24. Hobbs FD, Delaney BC, Rowsby M, Kenkre JE. Effect of Helicobacter pylori eradication therapy on dyspeptic symptoms in primary care. Fam Pract. 1996;13:225-8.
25. Weijnen CF, De Wit NJ, Numans ME, Quartero AO, Verheij TJ. Dyspepsia management in primary care in The Netherlands: to what extent is Helicobacter pylori diagnosis and treatment incorporated? Results from a survey among general practitioners in The Netherlands. Digestion. 2001;64:40-5.
26. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology. 1990;99:345-51.
27. Castell DO, Kahrilas PJ, Richter JE, Vakil NB, Johnson DA, Zuckerman S, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002;97:575-83.
28. Smith T, Verzola E, Mertz H. Low yield of endoscopy in patients with persistent dyspepsia taking proton pump inhibitors. Gastrointest Endosc. 2003;58:9-13.
29. Gisbert JP, Vázquez MA, Cantero J, Pajares JM. Estudio de la validez de la serología «rápida» para el estudio de la infección por Helicobacter pylori. Aten Primaria. 2002;30:501-6.
30. Phull PS, Halliday D, Price AB, Jacyna MR. Absence of dyspeptic symptoms as a test of Helicobacter pylori eradication. BMJ. 1996;312:349-50.
31. Gené E, Calvet X, Azagra R. Diagnosis of Helicobacter pylori after triple therapy in uncomplicated duodenal ulcers: a costeffectiveness analysis. Aliment Pharmacol Ther. 2000;14:433-42.